Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (66.7%)
N/A1 (33.3%)

Trials by Status

enrolling_by_invitation133%
recruiting267%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_1

CAR-T Cells for HIV Infection

NCT04648046
recruitingphase_1

The Tatelo Plus Study

NCT06508749
enrolling_by_invitationnot_applicable

Analytic Treatment Interruption (ATI) to Assess HIV Cure

NCT02437526

Clinical Trials (3)

Showing 3 of 3 trials
NCT04648046Phase 1

CAR-T Cells for HIV Infection

Recruiting
NCT06508749Phase 1

The Tatelo Plus Study

Recruiting
NCT02437526Not Applicable

Analytic Treatment Interruption (ATI) to Assess HIV Cure

Enrolling By Invitation

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3